Clarify Medical, a San Diego, CA-based provider of a home light therapy system for the treatment and monitoring of patients with chronic skin conditions, closed an $18M Series A financing.
Backers included H.I.G. BioHealth Partners, 7wire Ventures, SV Health Investors, and Bluestem Capital. In conjunction with the funding, Michael Wasserman, Managing Director of H.I.G. BioHealth Partners; Robert Garber, Partner at 7wire Ventures; and Paul LaViolette, Managing Partner and Chief Operating Officer of SV Health Investors, will join Clarify Medical’s board of directors.
The company intends to use the funds for the commercialization and further development of its therapy system.
Led by George Mahaffey, President & CEO, Clarify Medical medical device company focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Its Clarify System, which has been cleared by the FDA, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is a connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of targeted narrowband UVB (NB-UVB) light therapy.
The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision and achieve clinical efficacy in the convenience of their homes.
The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.